LinkedInFacebookTwitterRssEmail
(832) 968-8698|sales@avancebio.com

News

1 08, 2025

Avance New Site Tier One Commissioning Change Notification

2025-08-01T17:46:23+00:00

Avance Biosciences is proud to announce the partial commissioning of our new GMP facility at 5500 Northwest Central Drive in Houston, Texas. Effective July 21, 2025, select Biologics Quality Control services, including Microbiology and Sanger sequencing, will transition from our West Little York site to this new location. Please begin shipping samples directly to the new facility as we continue to expand our capabilities to better serve our clients.

Avance New Site Tier One Commissioning Change Notification2025-08-01T17:46:23+00:00
31 07, 2025

New Blog Series: Real-World NGS Case Studies for Biopharmaceutical Development

2025-10-22T20:59:42+00:00

Our new blog series explore how cutting-edge NGS technologies are being applied to solve real-world challenges in biopharmaceutical development. Follow along for insights into assay strategies, platform selection, and the measurable impact of our scientific approach...

New Blog Series: Real-World NGS Case Studies for Biopharmaceutical Development2025-10-22T20:59:42+00:00
10 07, 2025

Avance Biosciences Expands Bioanalytical Testing Capabilities with New LC-MS/MS Services

2025-10-22T20:59:52+00:00

Avance Biosciences now offers LC-MS/MS services to support precise bioanalytical testing for small molecules, peptides, oligonucleotides, and biomarkers, enhancing drug development with advanced PK/PD, impurity profiling, and targeted proteomics capabilities...

Avance Biosciences Expands Bioanalytical Testing Capabilities with New LC-MS/MS Services2025-10-22T20:59:52+00:00
24 06, 2025

Join Avance at the BioProcessing Summit – August 18-21, 2025

2025-10-22T21:00:03+00:00

Avance Biosciences™ is proud to announce its participation in the Bioprocessing Summit 2025 in Boston, MA. Visit Booth #516 to learn how our GLP- and GMP-compliant analytical services support the development and manufacturing of biologics, cell and gene therapies, and advanced biotherapeutics...

Join Avance at the BioProcessing Summit – August 18-21, 20252025-10-22T21:00:03+00:00
10 06, 2025

Avance is growing to better support biopharmaceutical drug development and manufacturing

2025-10-22T21:00:12+00:00

Our existing 28,000 sq. ft. of lab space is expanding by an additional 17,000 sq. ft., enhancing our GLP, GMP and CLIA testing capabilities...

Avance is growing to better support biopharmaceutical drug development and manufacturing2025-10-22T21:00:12+00:00
20 05, 2025

Groundbreaking Personalized Gene Therapy Saves Infant with Rare, Incurable Disease

2025-10-06T21:50:07+00:00

An NIH-supported team has delivered the first personalized CRISPR-based gene therapy to an infant with CPS1 deficiency, offering new hope for rare disease treatment. The customized approach shows early success and may pave the way for future individualized therapies...

Groundbreaking Personalized Gene Therapy Saves Infant with Rare, Incurable Disease2025-10-06T21:50:07+00:00
13 05, 2025

FDA Accelerates AI Integration to Transform Drug Review Processes

2025-10-06T21:46:09+00:00

The FDA is embracing AI to streamline drug reviews, aiming for full implementation by June 2025. Following a successful pilot, this move could fast-track therapy approvals and reduce administrative tasks for scientists...

FDA Accelerates AI Integration to Transform Drug Review Processes2025-10-06T21:46:09+00:00
6 05, 2025

Verve Therapeutics Reports Promising Results for PCSK9 Gene Editing in HeFH

2025-10-06T21:52:06+00:00

Verve Therapeutics’ VERVE-102 shows early success in lowering LDL cholesterol by 55% with a single dose, offering a potential one-time gene editing treatment for familial hypercholesterolemia...

Verve Therapeutics Reports Promising Results for PCSK9 Gene Editing in HeFH2025-10-06T21:52:06+00:00
29 04, 2025

MIT Engineers Develop Gene Circuit for Precise Control of Gene Therapy

2025-10-06T21:50:08+00:00

MIT engineers have developed a gene circuit that precisely controls gene expression, offering potential breakthroughs in gene therapy for disorders like fragile X syndrome. This advancement helps ensure therapeutic genes are expressed at optimal levels, minimizing risks and paving the way for more effective treatments...

MIT Engineers Develop Gene Circuit for Precise Control of Gene Therapy2025-10-06T21:50:08+00:00

About Us

Avance Biosciences is a leading Contract Research Organization (CRO) and Contract Testing Organization (CTO) providing CGMP and GLP-compliant analytical and bioanalytical services to support drug development. From early discovery through clinical development and commercialization, we provide CGMP and GLP-compliant services tailored to your therapeutic modality and regulatory needs.

NEWSLETTER SIGNUP

21 CFR Part 11 Compliant
FDA Inspected
CLIA Registered

CONTACT INFORMATION

  • 5500 NW Central Dr, Houston TX 77092

Recent News

Go to Top